FDA Cites GSC Products for Illegally Marketing Unapproved Over-the-Counter Drugs

The U.S. Food and Drug Administration issued a warning letter to GSC Products, LLC on May 18, 2026, for selling products that are considered unapproved new drugs and are misbranded under federal law. The agency’s action targets products marketed for over-the-counter (OTC) use that made therapeutic claims without undergoing the required FDA review and approval process.

The warning letter, identified by case number 729653, outlines the FDA's findings following a review of the company’s product labeling and online marketing materials. According to the agency, GSC Products made specific claims suggesting its products could treat, mitigate, or prevent diseases. Such claims legally classify a product as a “drug” under the Federal Food, Drug, and Cosmetic (FD&C) Act, requiring it to meet stringent pre-market approval standards to ensure its safety and efficacy for its intended use.

For a product to be legally marketed as an OTC drug in the United States, it must either conform to an established FDA monograph for a specific therapeutic category or receive approval through a New Drug Application (NDA). The OTC monograph system functions like a rulebook, outlining acceptable active ingredients, doses, formulations, and labeling for various categories like sunscreens, anti-dandruff shampoos, or acne treatments. Products that fall outside these established monographs, or that make novel claims, must go through the more rigorous and costly NDA process, which involves submitting extensive clinical trial data. The FDA's letter indicates that GSC Products' offerings did neither, instead marketing products with drug-like claims directly to consumers without the necessary regulatory clearance.

The “misbranded” charge often accompanies an “unapproved new drug” violation. A drug is considered misbranded if its labeling is false or misleading in any way, if it fails to bear the name and place of business of the manufacturer, or if it does not contain adequate directions for use for the conditions it purports to treat. For unapproved drugs, the FDA's long-standing position is that adequate directions for use cannot be written for the general public, as their safety and effectiveness have not been established by the agency. This violation underscores the FDA's dual mandate to protect consumers from both unsafe and ineffectively labeled products.

The warning letter requires GSC Products to respond within 15 working days, detailing the specific steps it has taken to correct the violations. This response must include a plan to cease the distribution of its unapproved and misbranded drugs. Failure to promptly and adequately address the issues raised by the FDA could lead to more severe enforcement actions. These can include seizure of the company's products, an injunction to halt operations, or even criminal prosecution against the company and its executives, which can carry significant financial penalties and prison sentences.

This action against GSC Products is part of a broader, ongoing effort by the FDA to police the rapidly growing market for wellness, cosmetic, and supplement products that often blur the line into making medical claims. Small and mid-sized companies are particularly vulnerable, as they may lack the extensive regulatory affairs departments and legal budgets common in larger pharmaceutical firms. The FDA's public posting of warning letters serves as a clear signal to the entire industry that unsubstantiated therapeutic claims will not be tolerated, regardless of a company's size.

In our experience, many business owners in the consumer packaged goods sector underestimate the severe financial fallout from regulatory actions like this one. An FDA warning letter is not merely a request to change website copy; it is the start of a costly and potentially business-ending process. The direct costs include legal fees, product reformulation, and new packaging, but the indirect costs are often far greater, encompassing product recalls, lost inventory, and damaged relationships with distributors and retailers. This is precisely why we view regulatory compliance not as a legal burden but as a fundamental component of financial risk management. Proactively assessing marketing claims and product classifications can prevent catastrophic interruptions to revenue and protect the company's valuation. For businesses navigating these complex rules, C&S Finance Group LLC provides guidance on managing these exact financial risks at csfinancegroup.com.

GSC Products' response to the FDA will now be closely monitored by industry observers and competitors. The company's corrective actions, and the agency's subsequent steps, will provide a current case study on the enforcement climate for OTC products. This event serves as a critical reminder to other businesses in the consumer health space about the importance of adhering to federal marketing and drug approval regulations before bringing a product to market.